key: cord-0893940-3i061600 authors: Sarkar, Soumya; Soni, Kapil Dev; Khanna, Puneet title: Convalescent plasma a clutch at straws in COVID‐19 management! A systematic review and meta‐analysis date: 2020-08-10 journal: J Med Virol DOI: 10.1002/jmv.26408 sha: 1ec93c150e850cd666e0e09c25cf4adf23eb96cc doc_id: 893940 cord_uid: 3i061600 BACKGROUND: In absence of definitive therapy for coronavirus disease (COVID‐19), convalescent plasma therapy (CPT) may be a critical therapeutic option. This review was conducted to evaluate the impact of CPT in COVID‐19 patients based on the publications reported to date. METHODS: A robust screening of electronic databases was conducted up to 10(th) July 2020. The randomized controlled trials (RCTs), cohort studies, and case series with control group evaluating the effectiveness and safety of CPT in patients with COVID‐19 are included for the meta‐analyses. RESULTS: Our search retrieved seven studies, including two RCTs and five cohort studies, with a total of 5,444 patients. In patients with COVID‐19, the use of CPT reduces mortality [Odd's ratio (OR) 0.44, 95% CI 0.25 to 0.77], increases viral clearance [OR 11.29, 95% CI 4.9 to 25.9] and improves clinically [OR 2.06, 95% CI 0.8 to 4.9].However, the evidences are of low quality (mortality reduction, and viral clearance),and very low quality (clinical improvement). CONCLUSIONS: CPT may be beneficial for reducing mortality, viral shedding. and improving clinical conditions in COVID‐19 patients. However, further randomized control trials (RCT) are required to substantiate the safety margin, initiation, optimal dosage, titre and duration of CPT. This article is protected by copyright. All rights reserved. independently by two researchers (SS & PK). The following terminologies: ("COVID-19") OR ("SARS-CoV-2") AND ("plasma" OR "convalescent plasma") were searched. We included randomized controlled trials (RCT), controlled clinical trials, prospective and retrospective comparative cohort studies, case-control studies; cross-sectional studies, and case series with a control group on steroid therapy for COVID -19 patients. Our primary outcome of interest was mortality, and secondary outcomes included improvement in clinical conditions and clearance of viral shedding. We excluded articles written in languages other than English, absence of essential data, and without retrievable full text (PRISMA flow diagram). 10-11 . The available literature was screened independently after the removal of duplications by two researchers (SS and KDS). We screened all the abstracts primarily to exclude irrelevant articles. Finally, full-texts of the potentially eligible studies were screened for inclusion. Disagreements were consulted with a third researcher (PK). Two researchers (SS and KDS) extracted the data independently from all included studies with the use of pre-conceived data extraction sheet. The Extracted information contained details of the intervention and control groups, mortality, clinical improvement, and viral clearance. The number of events along with the total number Accepted Article of patients per group was extracted for dichotomous data. Studies with missing or unusable data are reported in findings descriptively. Two researchers (SS & PK) assessed the potential bias in each selected study independently. The third researcher (KDs)was consulted for resolving any difference of opinion. The RoB 2.0 tool 12 , was used for RCTs, which includes five domains: "randomization process", "deviations from intended interventions", "missing outcome data", "measurement of the outcome", and "selection of the reported result". We used the Risk Of Bias In Non-randomized Studies -of Interventions (ROBINS-I) 13 tool for assessing the risk of bias in non-randomized studies. It comprises of seven domains: "bias due to confounding", "selection of participants, classification of interventions", "deviations from intended interventions", "missing data", "measurement of outcomes", and "selection of the reported result". Each domain is graded as "Low", "Moderate", "Serious", and "Critical". Two experienced researchers (PK & KDS) evaluated the quality of evidence by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. 14-15 It has five downgrading factors (study limitations, consistency of effect, imprecision, indirectness, and publication bias) and three upgrading factors (large magnitude of the effect, dose-response relation, and plausible confounders or biases). The quality of evidence of each outcome is classified as "High", "Moderate", "Low" or "Very low". [16] [17] [18] [19] [20] [21] [22] This article is protected by copyright. All rights reserved. Review manager version 5.4 was used for conducting the meta-analysis. The Odd's ratio (OR) with 95% confidence intervals (CIs) was assessed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions 23 . Statistical heterogeneity was assessed with the I 2 statistic, >50% indicating substantial heterogeneity. Funnel plot was used to assess publication bias. The present study was not registered for rapid decision making in the context of the ongoing public health emergency. We included seven studies (two RCTs and five cohort studies) out of 679 identified publications in this rapid review, after satisfying the inclusion criteria. (Figure 1) ( Table 1 ). The risk of bias was low in one of the included RCTs and the other one had some concerns. (Figure 2a) . Out of the rest five studies, four studies have been associated with a moderate degree of bias. (Figure 2b) Mortality was assessed in seven articles (two RCTs and five cohort studies) with a total of 5,444 patients. The use of CPT reduced the risk of mortality almost by half in COVID-19 (OR =0.44, 95% CI 0.25 to 0.77, I 2 =0), which is statistically significant Five studies with a total of 259 patients assessed the clinical improvement in COVID- 19 . The majority of the COVID-19 patients who received CPT showed clinical Accepted Article improvement than in patients who received no CPT (OR 2.06, 95% CI 0.8 to 4.9, I 2 =44%;), ( Figure 4a ). However, the finding is not statistically significant. The incidence of viral clearance was assessed in two studies with a total of 144 patients. It is found that the use of CPT helps in viral clearance (OR 11.29, 95% CI 4.9 to 25.9, I 2 =0%;) significantly. (Figures 4b) . Apert form mild heterogeneity among studies on assessing clinical improvement (I 2 =44), the overall findings are homogenous. In view of the high homogeneity, the overall effect seems to be conclusive. The quality of evidence on the impact of CPT on mortality and viral clearance in COVID-19 is of low quality, and clinical improvement is of very low quality ( Table 2 ). We assessed publication bias for the studies on COVID-19 mortality. The Funnel plot indicates a publication bias is likely in view of smaller studies with large effect. (Supplemental Figure 1) 4. Discussion: 4.1. We have identified low-quality evidence with variability that the convalescent plasma therapy is associated with around 44% reduction in the mortality in COVID- Similar systematic review and meta-analysis on severe acute respiratory syndrome (SARS), reported that the CPT is beneficial for reducing the (OR, 0.25; 95% confidence interval, .14-.45; I 2 = 0%) in comparison to placebo or no therapy. 31 Another recent systematic review on CPT in COVID-19 patients reported about a potential reduction in mortality but unable to provide any opinion regarding the efficacy of CPT in COVID-19 due to paucity in quantitative synthesis 32 The present study has identified a very low-quality evidence regarding improvement in clinical conditions and a low-quality evidence for viral clearance, are associated with CPT. A recent systematic review on the efficacy of CPT for the management of COVID-19 also reported a significant decrease in Viral loads and improvement in clinical symptoms within 3-26 days post-transfusion. 33 The convalescent sera option for containing COVID-19 Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks.Geneva: World Health Organization Use of convalescent plasma therapy in SARS patients in Hong Kong HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables GRADE guidelines: 3. Rating the quality of evidence GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias) GRADE guidelines: 5. Rating the quality of evidence-publication bias GRADE guidelines 6. Rating the quality of evidence--imprecision GRADE guidelines: 7. Rating the quality of evidence--inconsistency GRADE guidelines: 8. Rating the quality of evidence--indirectness GRADE guidelines: 9. Rating up the quality of evidence Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions Convalescent plasma transfusion for the treatment of COVID-19: Systematic review Safety and efficacy of convalescent plasma therapy for the management of COVID-19: A systematic review Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis Treatment of COVID-19 Patients with Convalescent Plasma in